BACKGROUND AND AIMS: Antiphospholipid Syndrome (APS) is often complicated by ischemic vascular events. Vitamin K Antagonists (VKAs) reduce the risk of recurrent thrombosis. Quality of VKAs treatment, as assessed by the Time in Therapeutic Range (TTR), has never been investigated in APS patients. METHODS: We performed a prospective observational study including 30 APS and 30 Atrial Fibrillation (AF) patients balanced by age and gender. All patients were treated with VKAs (INR target 2.5), and TTR was calculated. RESULTS: Median TTR of APS was 53.5% vs. 68% of AF patients (p = 0.001). A multivariable linear regression analysis confirmed that the presence of APS (vs. AF) was independently associated with a worse TTR (B: -14.067, 95% Confidence Interval -25.868/-2.266, p = 0.020). The weekly dosage of VKAs was significantly higher in APS than AF patients. CONCLUSIONS: APS patients disclose a lower quality of anticoagulation compared to those with AF, requiring higher doses of VKAs. The efficacy of non-vitamin K oral anticoagulants in this high-risk patients should be tested.

Antiphospholipid syndrome and anticoagulation quality: A clinical challenge / Pastori, Daniele; Parrotto, Sandro; Vicario, Tommasa; Saliola, Mirella; Mezzaroma, Ivano; Violi, Francesco; Pignatelli, Pasquale. - In: ATHEROSCLEROSIS. - ISSN 0021-9150. - ELETTRONICO. - 244:(2016), pp. 48-50. [10.1016/j.atherosclerosis.2015.10.105]

Antiphospholipid syndrome and anticoagulation quality: A clinical challenge

PASTORI, DANIELE;VICARIO, TOMMASA;SALIOLA, Mirella;MEZZAROMA, Ivano;VIOLI, Francesco;PIGNATELLI, Pasquale
2016

Abstract

BACKGROUND AND AIMS: Antiphospholipid Syndrome (APS) is often complicated by ischemic vascular events. Vitamin K Antagonists (VKAs) reduce the risk of recurrent thrombosis. Quality of VKAs treatment, as assessed by the Time in Therapeutic Range (TTR), has never been investigated in APS patients. METHODS: We performed a prospective observational study including 30 APS and 30 Atrial Fibrillation (AF) patients balanced by age and gender. All patients were treated with VKAs (INR target 2.5), and TTR was calculated. RESULTS: Median TTR of APS was 53.5% vs. 68% of AF patients (p = 0.001). A multivariable linear regression analysis confirmed that the presence of APS (vs. AF) was independently associated with a worse TTR (B: -14.067, 95% Confidence Interval -25.868/-2.266, p = 0.020). The weekly dosage of VKAs was significantly higher in APS than AF patients. CONCLUSIONS: APS patients disclose a lower quality of anticoagulation compared to those with AF, requiring higher doses of VKAs. The efficacy of non-vitamin K oral anticoagulants in this high-risk patients should be tested.
Antiphospholipid syndrome; Time in therapeutic range; Warfarin; Cardiology and Cardiovascular Medicine
01 Pubblicazione su rivista::01a Articolo in rivista
Antiphospholipid syndrome and anticoagulation quality: A clinical challenge / Pastori, Daniele; Parrotto, Sandro; Vicario, Tommasa; Saliola, Mirella; Mezzaroma, Ivano; Violi, Francesco; Pignatelli, Pasquale. - In: ATHEROSCLEROSIS. - ISSN 0021-9150. - ELETTRONICO. - 244:(2016), pp. 48-50. [10.1016/j.atherosclerosis.2015.10.105]
File allegati a questo prodotto
File Dimensione Formato  
Pastori_Antiphospholipid Syndrome_2016.pdf

solo utenti autorizzati

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Creative commons
Dimensione 299.37 kB
Formato Adobe PDF
299.37 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/854020
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 12
social impact